Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig + nab-paclitaxel versus pembrolizumab + nab-paclitaxel in first-line PD-L1-positive advanced triple-negative breast cancer
PACTR202405736542144Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) comparing Tobemstomig plus nab-paclitaxel with Pembrolizumab plus nab-paclitaxel (2 arms). Primary endpoint: Progression-Free Survival. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on PACTR202405736542144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405736542144.